# Ewing Sarcoma of the Maxilla: An Uncommon Anatomical Presentation in a Young Patient

**Authors:** José R Velázquez-Soto, Daniel Rosales-Rosales, Carlos A Jaimes-Loreto, Lizeth R Ríos-Bañuelos, Rachel V Cárdenas-Cabral, Quitzia L Torres-Salazar

PMC · DOI: 10.7759/cureus.100129 · Cureus · 2025-12-26

## TL;DR

A rare case of Ewing sarcoma in the maxilla of a young woman is reported, highlighting the importance of early diagnosis and multidisciplinary treatment for successful outcomes.

## Contribution

This paper presents a rare anatomical presentation of Ewing sarcoma in the maxilla and emphasizes the role of multidisciplinary management in treatment.

## Key findings

- The patient achieved complete surgical excision with histologically negative margins.
- At 18 months of follow-up, there was no evidence of local recurrence.
- Multidisciplinary management preserved oral function and aesthetic outcomes.

## Abstract

Ewing sarcoma (ES) of the maxilla is an exceptionally rare entity that can mimic odontogenic or inflammatory conditions, often resulting in diagnostic delay. We report the case of a 23-year-old female who presented with a painless, progressively enlarging swelling of the anterior maxilla. Imaging demonstrated an expansile osteolytic lesion with cortical disruption. Histopathologic evaluation revealed a small round cell neoplasm, and immunohistochemical analysis showed diffuse membranous expression of cluster of differentiation 99 (CD99) and focal nuclear positivity for Friend leukemia integration 1 (FLI-1), supporting the diagnosis within the ES family of tumors in the appropriate clinicoradiologic context. The patient underwent subtotal maxillectomy with intraoperative margin assessment, achieving complete surgical excision with histologically negative margins, followed by adjuvant chemotherapy with epirubicin, cisplatin, and ifosfamide, as well as localized radiotherapy. At 18 months of clinical and radiologic follow-up, there was no evidence of local recurrence, with preserved oral function and satisfactory aesthetic outcomes on clinical evaluation. This report highlights the importance of considering malignant small round cell tumors in rapidly enlarging maxillofacial lesions and emphasizes the role of multidisciplinary management in achieving sustained local disease control while preserving postoperative function.

## Linked entities

- **Proteins:** CD99 (CD99 molecule (Xg blood group)), FLI1 (Fli-1 proto-oncogene, ETS transcription factor)
- **Chemicals:** epirubicin (PubChem CID 41867), cisplatin (PubChem CID 5460033), ifosfamide (PubChem CID 3690)
- **Diseases:** Ewing sarcoma (MONDO:0012817)

## Full-text entities

- **Genes:** FLI1 (Fli-1 proto-oncogene, ETS transcription factor) [NCBI Gene 2313] {aka BDPLT21, EWSR2, FLI-1, SIC-1}
- **Diseases:** round cell tumors (MESH:D058405), maxillofacial lesions (MESH:D008446), neoplasm (MESH:D009369), ES (MESH:D012512), odontogenic (MESH:D018126), swelling (MESH:D004487), osteolytic lesion (MESH:D030981), inflammatory conditions (MESH:D007249)
- **Chemicals:** epirubicin (MESH:D015251), cisplatin (MESH:D002945), ifosfamide (MESH:D007069)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12832077/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12832077/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12832077/full.md

---
Source: https://tomesphere.com/paper/PMC12832077